中国医院用药评价与分析2026，Vol.26Issue(3)：261-265,269,6.DOI:10.14009/j.issn.1672-2124.2026.03.002
基于大规模真实世界数据的人促红细胞生成素与罗沙司他治疗肾性贫血的比较性研究
Comparative Study of Human Erythropoietin and Roxadustat in the Treatment of Renal Anemia Based on Large-Scale Real-World Data
摘要
Abstract
OBJECTIVE:To compare and analyze the efficacy and economy of erythropoietin and roxadustat in the treatment of renal anemia based on large-scale real-world clinical data,and to provide evidence-based basis for clinical treatment selection and refined health insurance management.METHODS:Medical insurance settlement lists and inpatient electronic medical records of renal anemia patients were collected from 83 medical institutions across three coordinated regions in China from Dec.2022 to Jun.2025,samples treated with either human erythropoietin or roxadustat were enrolled.Descriptive statistics were used to analyze the distribution of monotherapy and switching medication patterns in real-world clinical practice.Under the monotherapy pattern,efficacy was assessed by hemoglobin growth rate,treatment effectiveness rate,hemoglobin response rate,and hemoglobin target achievement rate,while economic outcomes were evaluated using average drug cost per admission and total hospitalization cost.RESULTS:A total of 10 916 patients were included.Regarding treatment patterns,61.35％of patients(6 697 cases)received erythro-poietin as monotherapy,15.52％(1 694 cases)were treated with roxadustat alone,while 23.13％(2 525 cases)underwent switching therapy between these two agents.Regarding efficacy,the human erythropoietin group showed higher hemoglobin growth rate(16.31％vs.10.46％),effective rate(73.57％vs.68.92％),hemoglobin response rate(36.34％vs.28.41％)and hemoglobin target achievement rate(21.24％vs.17.75％)than those in the roxadustat group after treatment,with statistically significant differences(P<0.05).In terms of economic outcomes,the erythropoietin group had significantly lower average drug costs per hospitalization(127 RMB vs.752 RMB)and total hospitalization costs(7 980 RMB vs.8 437 RMB)than those in the roxadustat group,with statistically significant differences(P<0.001).Multivariate regression analysis yielded results consistent with the above conclusions.CONCLUSIONS:Based on large-scale real-world retrospective cohort data,human erythropoietin remains the main treatment for renal anemia,showing certain advantages in efficacy and clear economic benefits.As an innovative oral agent,roxadustat has been increasingly used in clinical practice and offers an additional therapeutic option for renal anemia.关键词
人促红细胞生成素/罗沙司他/肾性贫血/临床用药模式/疗效/经济性Key words
Human erythropoietin/Roxadustat/Renal anemia/Clinical medication pattern/Efficacy/Economical efficiency分类
医药卫生引用本文复制引用
刘喜恩,金松,唐建宇,张欢,吴及..基于大规模真实世界数据的人促红细胞生成素与罗沙司他治疗肾性贫血的比较性研究[J].中国医院用药评价与分析,2026,26(3):261-265,269,6.基金项目
国家医疗保障局相关专项委托项目"平台价格异常穿透模型研究"和"关于人工智能在医保支付分组方案的研究" （）
